CD74-ROS1 fusion transcripts in resected non-small cell lung carcinoma

Oncology Reports

Volumn 30, Issue 4, 2013, Pages 1675-1680

  Matsuura, Shun ^a   Shinmura, Kazuya ^a   Kamo, Takaharu ^a   Igarashi, Hisaki ^a   Maruyama, Kyoko ^a   Tajima, Mari ^a   Ogawa, Hiroshi ^b   Tanahashi, Masayuki ^b   Niwa, Hiroshi ^b   Funai, Kazuhito ^a   Kohno, Takashi ^c   Suda, Takafumi ^a   Sugimura, Haruhiko ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SEIREI MIKATAHARA GENERAL HOSPITAL   (Japan)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

ALK; CD74; Fusion gene; Non small cell lung carcinoma; RET; ROS1

Indexed keywords

B RAF KINASE; CD74 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN RET; PROTEIN ROS1; PROTEIN TYROSINE KINASE; SODIUM PHOSPHATE COTRANSPORTER 2B; UNCLASSIFIED DRUG;

AGED; ALK GENE; ARTICLE; BRAF GENE; CONTROLLED STUDY; EGFR GENE; EXON; FEMALE; FUSION GENE; GENE; GENE FUSION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; ONCOGENE K RAS; PIK3CA GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE;

ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; KINESIN; LUNG NEOPLASMS; MALE; ONCOGENE PROTEINS, FUSION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SODIUM-PHOSPHATE COTRANSPORTER PROTEINS, TYPE IIB; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84882576021     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2630     Document Type: Article

References (24)

1. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y and Mano H: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448: 561-566, 2007.
2. Shinmura K, Kageyama S, Tao H, Bunai T, Suzuki M, Kamo T, Takamochi K, Suzuki K, Tanahashi M, Niwa H, Ogawa H and Sugimura H: EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas. Lung Cancer 61: 163-169, 2008.
3. Shinmura K, Kageyama S, Igarashi H, Kamo T, Mochizuki T, Suzuki K, Tanahashi M, Niwa H, Ogawa H and Sugimura H: EML4-ALK fusion transcripts in immunohistochemically ALK-positive non-small cell lung carcinomas. Exp Ther Med 1: 271-275, 2010.
4. Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, Asaka R, Hamanaka W, Ninomiya H, Uehara H, Lim Choi Y, Satoh Y, Okumura S, Nakagawa K, Mano H and Ishikawa Y: RET, ROS1 and ALK fusions in lung cancer. Nat Med 18: 378-381, 2012.
5. Lipson D, Capelletti M, Yelensky R, Otto G, Parker A, Jarosz M, Curran JA, Balasubramanian S, Bloom T, Brennan KW, Donahue A, Downing SR, Frampton GM, Garcia L, Juhn F, Mitchell KC, White E, White J, Zwirko Z, Peretz T, Nechushtan H, Soussan-Gutman L, Kim J, Sasaki H, Kim HR, Park SI, Ercan D, Sheehan CE, Ross JS, Cronin MT, Jänne PA and Stephens PJ: Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 18: 382-384, 2012.
6. Casaluce F, Sgambato A, Maione P, Rossi A, Ferrara C, Napolitano A, Palazzolo G, Ciardiello F and Gridelli C: ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC. Target Oncol 8: 55-67, 2013.
7. Shaw AT and Solomon B: Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res 17: 2081-2086, 2011.
8. O'Bryant CL, Wenger SD, Kim M and Thompson LA: Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer. Ann Pharmacother 47: 189-197, 2013.
9. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, Nardone J, Lee K, Reeves C, Li Y, Hu Y, Tan Z, Stokes M, Sullivan L, Mitchell J, Wetzel R, Macneill J, Ren JM, Yuan J, Bakalarski CE, Villen J, Kornhauser JM, Smith B, Li D, Zhou X, Gygi SP, Gu TL, Polakiewicz RD, Rush J and Comb MJ: Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131: 1190-1203, 2007.
10. Li C, Fang R, Sun Y, Han X, Li F, Gao B, Iafrate AJ, Liu XY, Pao W, Chen H and Ji H: Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers. PLoS One 6: e28204, 2011.
11. Kohno T, Ichikawa H, Totoki Y, Yasuda K, Hiramoto M, Nammo T, Sakamoto H, Tsuta K, Furuta K, Shimada Y, Iwakawa R, Ogiwara H, Oike T, Enari M, Schetter AJ, Okayama H, Haugen A, Skaug V, Chiku S, Yamanaka I, Arai Y, Watanabe S, Sekine I, Ogawa S, Harris CC, Tsuda H, Yoshida T, Yokota J and Shibata T: KIF5B-RET fusions in lung adenocarcinoma. Nat Med 18: 375-377, 2012.
12. Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang R, Mark EJ, Batten JM, Chen H, Wilner KD, Kwak EL, Clark JW, Carbone DP, Ji H, Engelman JA, Mino-Kenudson M, Pao W and Iafrate AJ: ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30: 863-870, 2012.
13. Seo JS, Ju YS, Lee WC, Shin JY, Lee JK, Bleazard T, Lee J, Jung YJ, Kim JO, Shin JY, Yu SB, Kim J, Lee ER, Kang CH, Park IK, Rhee H, Lee SH, Kim JI, Kang JH and Kim YT: The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res 22: 2109-2119, 2012.
14. Davies KD, Le AT, Theodoro MF, Skokan MC, Aisner DL, Berge EM, Terracciano LM, Cappuzzo F, Incarbone M, Roncalli M, Alloisio M, Santoro A, Camidge DR, Varella-Garcia M and Doebele RC: Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res 18: 4570-4579, 2012.
15. Rimkunas VM, Crosby KE, Li D, Hu Y, Kelly ME, Gu TL, Mack JS, Silver MR, Zhou X and Haack H: Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res 18: 4449-4457, 2012.
16. Yokota K, Sasaki H, Okuda K, Shimizu S, Shitara M, Hikosaka Y, Moriyama S, Yano M and Fujii Y: KIF5B/RET fusion gene in surgically-treated adenocarcinoma of the lung. Oncol Rep 28: 1187-1192, 2012.
17. Yoshida A, Kohno T, Tsuta K, Wakai S, Arai Y, Shimada Y, Asamura H, Furuta K, Shibata T and Tsuda H: ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical sases. Am J Surg Pathol 37: 554-562, 2013.
18. Schmid K, Oehl N, Wrba F, Pirker R, Pirker C and Filipits M: EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin Cancer Res 15: 4554-4560, 2009.
19. Pao W and Girard N: New driver mutations in non-small-cell lung cancer. Lancet Oncol 12: 175-180, 2011.
20. Ulivi P, Romagnoli M, Chiadini E, Casoni GL, Capelli L, Gurioli C, Zoli W, Saragoni L, Dubini A, Tesei A, Amadori D and Poletti V: Assessment of EGFR and K-ras mutations in fixed and fresh specimens from transesophageal ultrasound-guided fine needle aspiration in non-small cell lung cancer patients. Int J Oncol 41: 147-152, 2012.
21. Thomas M, Kalita A, Labrecque S, Pim D, Banks L and Matlashewski G: Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 19: 1092-1100, 1999.
22. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
23. Rodig SJ, Mino-Kenudson M, Dacic S, Yeap BY, Shaw A, Barletta JA, Stubbs H, Law K, Lindeman N, Mark E, Janne PA, Lynch T, Johnson BE, Iafrate AJ and Chirieac LR: Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 15: 5216-5223, 2009.
24. Jokoji R, Yamasaki T, Minami S, Komuta K, Sakamaki Y, Takeuchi K and Tsujimoto M: Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinoma. J Clin Pathol 63: 1066-1070, 2010.